Status:
COMPLETED
Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Sickle Cell Anaemia
Lead Sponsor:
Liverpool School of Tropical Medicine
Collaborating Sponsors:
University of Bergen
University of Malawi
Conditions:
Sickle Cell Anemia in Children
Malaria
Eligibility:
All Genders
6-15 years
Phase:
PHASE3
Brief Summary
Sickle Cell Anaemia (SCA) is an inherited disease that makes the body produce red blood cells with abnormal sickle-shaped cells. The sickle-shaped cells are rigid, not flexible and break up easily res...
Detailed Description
Background and rationale: An estimated 300,000 babies are born with Sickle Cell Anaemia (SCA) annually. Affected children have chronic ill health and many suffer a premature death. Ill health is comm...
Eligibility Criteria
Inclusion
- Inclusion criteria
- Children ages 6 months - 15 years
- Has a laboratory diagnosis of Sickle Cell Anaemia (HbSS) on haemoglobin electrophoresis, High-Performance Liquid Chromatography or Iso-electric focusing;
- Weighs ≥5kg;
- The parent has provided written consent.
- Exclusion Criteria:
- Known chronic disease e.g. congenital heart disease;
- Known red cell disorder e.g. thalassaemia, glucose-6-phosphate dehydrogenase deficiency;
- Known allergy to DP or SP;
- Receiving daily cotrimoxazole prophylaxis;
- Unlikely to comply with the follow-up schedule;
- Participating in another trial
Exclusion
Key Trial Info
Start Date :
April 9 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 12 2023
Estimated Enrollment :
723 Patients enrolled
Trial Details
Trial ID
NCT04844099
Start Date
April 9 2021
End Date
July 12 2023
Last Update
September 13 2023
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Queen Elizabeth Hospital
Blantyre, Malawi
2
Jinja Regional Referral hospital
Jinja, Uganda
3
Kitgum General Hospital
Kitgum, Uganda